The management of autonomic disease encompasses a number of aspects. Of immediate and practical importance is alleviation of symptoms. The ideal is to rectify the autonomic deficit and cure the underlying disorder. Autonomic disease often involves various systems, and principles in relation to management of the major clinical features are provided. Specific aspects will vary in different diseases and always should be directed to the needs of the individual.

**CARDIOVASCULAR SYSTEM**

**Orthostatic hypotension**

Orthostatic (postural) hypotension may cause few symptoms in some but considerable morbidity in others. It may contribute to disability and even death, because of the potential risk of substantial injury. Treatment may be needed even in those who are asymptomatic, as in situations such as fluid depletion or treatment with drugs that have vasodilator effects, there may be pronounced falls in blood pressure with serious sequelae. Understanding the pathophysiological basis of orthostatic hypotension, and the associated disease process that influences it, often is necessary in the individual.

Blood pressure maintenance is dependent on beat-by-beat control exerted by the sympathetic nervous system, on cardiac output, on tone in resistance and capacitance vessels (which also is influenced by systemic and local pressor and depressor hormones), and on intravascular fluid volume. No single drug or treatment can effectively mimic the actions of the sympathetic nervous system in different situations and a multipronged approach, combining non-pharmacological and pharmacological measures, usually is needed (table 1). The doctor and patient should be aware of the limitations of treatment. Furthermore, associated deficits (such as cerebellar features in multiple system atrophy) may limit mobility in some, despite effective treatment of orthostatic hypotension.

Increasing patient awareness of factors that lower blood pressure is important. Rapid postural change, especially in the morning when getting out of bed, must be avoided because the supine blood pressure often is lowest at this time. Prolonged bed rest and recumbency through factors that include decompensation may contribute to orthostatic intolerance, even in healthy individuals, and can considerably worsen orthostatic hypotension in autonomic failure. Head-up tilt at night is beneficial and may reduce salt and water loss by stimulating the renin–angiotensin–aldosterone system. Straining during micturition and defaecation lowers blood pressure further by inducing a Valsalva manoeuvre. In toilets in small enclosed areas this is dangerous because of the inability to fall to the floor and thereby recover blood pressure and consciousness. In hot weather, because of impairment of thermoregulatory mechanisms, the rise in body temperature will increase cutaneous vasodilatation and worsen orthostatic hypotension. Ingestion of alcohol or large meals, especially those with a high carbohydrate content, causes splanchnic vasodilatation and postprandial hypotension, which aggravate orthostatic hypotension. Ingestion of alcohol or large meals, especially those with a high carbohydrate content, causes splanchnic vasodilatation and postprandial hypotension, which aggravate orthostatic hypotension. Various physical manoeuvres such as leg crossing, squatting, sitting in the knee-chest position, and abdominal compression, reduce orthostatic hypotension (fig 1). Drugs needed for associated symptoms (such as dopaminergic agents for parkinsonism) or to improve quality of life (sildenafil for erectile failure), may lower blood pressure further.

Lower limb elastic stockings, abdominal binders, and positive gravity suits reduce venous pooling during standing. Each has its limitations and may increase susceptibility to orthostatic hypotension when not in use. Water ingestion (250–500 ml) raises blood pressure substantially in primary autonomic failure by mechanisms that remain unclear. The ensuing diuresis may be troublesome, especially in multiple system atrophy (MSA) with associated urinary bladder disturbances.

Drugs often are needed in association with non-pharmacological measures in moderate to severe orthostatic hypotension. They may act in a variety of ways to raise blood pressure; by constricting blood vessels, increasing cardiac output, preventing vasodilatation, and retaining salt and water.

A valuable starter drug is fludrocortisone in a dose of 50–100 µg at night. Although there is no evidence of a mineralocorticoid deficiency in primary autonomic failure, it acts by retaining salt
and water and increasing the sensitivity of blood vessels to pressor substances. Body weight may increase. In some ankle oedema, and with higher doses hyperkalaemia, may result.

The second line of drugs include those that mimic the actions of noradrenaline (norepinephrine). Sympathomimetics include ephedrine, used in a dose of 15 mg three times daily that can be increased to 30 or 45 mg three times daily. It acts both directly and indirectly. It raises blood pressure in central and incomplete autonomic lesions, including MSA. Tachycardia, tremor, and insomnia may limit use of higher doses. In peripheral lesions, such as pure autonomic failure (PAF) and diabetic autonomic neuropathy, where ephedrine may not be effective, midodrine is used. It is converted to the active metabolite, desglymidodrine, that acts on α adrenoceptors. An initial dose of 2.5 mg three times daily can be increased gradually to 10 mg three times daily. Its side effects include a tingling scalp, goose bumps, and in the male urinary retention. Knowledge of the precise biochemical deficit enables selective use of drugs that bypass the autonomic deficit, as in dopamine β hydroxylase (DBH) deficiency, where the amino acid, l-threo-3, 4-dihydroxyphenylserine is converted by dopa-decarboxylase into noradrenaline (fig 2). Sympathomimetic drugs act mainly on resistance vessels and consideration should be given to the potential risk of deleterious arterial constriction, especially in the elderly and those with peripheral vascular disease. The ergot alkaloid, dihydroergotamine, acts predominantly on venous capacitance vessels, but its effects are limited by its poor absorption necessitating high oral doses (5–10 mg three times daily).

Specific targeting of pathophysiological mechanisms should be introduced when the combination of fludrocortisone and sympathomimetics is not effective. Nocturnal polyuria often worsens morning orthostatic hypotension. The vasopressin-2 receptor agonist, desmopressin, is a potent antidiuretic with minimal direct pressor activity. It is used in a dose of 5–40 μg intranasally or 100–400 mg orally at night to reduce diuresis. It ideally needs to be used with fludrocortisone to prevent nocturnal natriuresis. In MSA, with nocturia also caused by bladder disturbances, it may be of considerable benefit in reducing disturbed sleep. Smaller doses are needed in PAF who appear more sensitive than MSA. Plasma sodium should be measured at intervals to exclude hyponatraemia. Water intoxication can be reversed by stopping the drug, and withholding water.

In postprandial hypotension large meals should be avoided and small meals with low carbohydrate content eaten at frequent intervals. Drinking coffee after meals may help. Caffeine blocks vasodilatatory adenosine receptors, and a dose of 250 mg (present in two cups of coffee) can be used; tolerance may develop. The somatostatin analogue, octreotide, prevents postprandial hypotension by inhibiting release of a variety of

---

**Table 1** Some of the approaches used in the management of orthostatic hypotension

<table>
<thead>
<tr>
<th>Non-pharmacological measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>To be avoided</td>
</tr>
<tr>
<td>– sudden head-up postural change (especially on waking)</td>
</tr>
<tr>
<td>– prolonged recumbency</td>
</tr>
<tr>
<td>– straining during micturition and defaecation</td>
</tr>
<tr>
<td>– high environmental temperature (including hot baths)</td>
</tr>
<tr>
<td>– “severe” exertion</td>
</tr>
<tr>
<td>– large meals (especially with refined carbohydrate)</td>
</tr>
<tr>
<td>– alcohol</td>
</tr>
<tr>
<td>– drugs with vasodepressor properties</td>
</tr>
</tbody>
</table>

| To be introduced            |
| – head-up tilt during sleep |
| – small frequent meals      |
| – High salt intake          |
| – judicial exercise (including swimming)                    |
| – body positions and manoeuvres                             |

| To be considered           |
| – elastic stockings        |
| – abdominal binders        |
| – water ingestion          |

<table>
<thead>
<tr>
<th>Pharmacological measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starter drug</td>
</tr>
<tr>
<td>– Fludrocortisone</td>
</tr>
<tr>
<td>– Ephedrine, midodrine</td>
</tr>
<tr>
<td>Specific targeting</td>
</tr>
<tr>
<td>– Octreotide, desmopressin, erythropoietin</td>
</tr>
</tbody>
</table>

vasodilator gastrointestinal peptides; it also may reduce postural and exercise induced hypotension. It is administered subcutaneously, in a dose of 25 or 50 μg, ideally 30 minutes before food ingestion. Its side effects include abdominal colic and loose stools that respond to spasmyotics (buscopan) and opiates (codeine phosphate and loperamide). Octreotide does not appear to enhance supine nocturnal hypertension.

Anaemia worsens the symptoms of orthostatic hypotension. It may occur in primary autonomic failure and when renal impairment complicates diabetes mellitus and systemic amyloidosis. Erythropoietin raises red cell mass and haemoglobin concentrations and reduces orthostatic hypotension and its symptoms in such situations.

Difficulties in the management of orthostatic hypotension have resulted in a vast array of drugs that in individual cases, or certain disorders, have been reported to provide benefit (table 2). When the drugs listed in table 1 fail, these could be considered. As with all drugs they should be used cautiously. Some have serious side effects such as cardiac failure with pindolol, and gastric ulceration and haemorrhage with indomethacin. The use of a noradrenaline pump in extreme cases has been beneficial.

Drugs to prevent orthostatic hypotension should be used to reduce the side effects of treatment that is essential for associated disease. When levodopa (L-dopa) is used to treat parkinsonism, higher doses of dopa-decarboxylase inhibitors should be used. The dopamine antagonists metoclopramide and domperidone also reduce the peripheral effects of dopamine.

**Supine hypertension**

Supine hypertension is frequently observed in primary autonomic failure and may be worsened by drug treatment. It is unclear if certain drugs, such as higher doses of fludrocortisone, are more likely to cause it. Supine hypertension may increase symptoms of cerebral ischaemia during postural change through an unfavourable resetting of cerebral autoregulatory mechanisms. Head-up tilt especially at night is probably the most practical method for preventing nocturnal supine hypertension. Omission of the evening dose of vasopressor agents, a pre-bedtime snack or alcohol to induce postprandial hypotension, and sometimes even use of short acting antihypertensive drugs, should be considered.

The long term effects of supine hypertension include cardiac hypertrophy and damage to subcortical cerebral vessels. This may occur in PAF who have a good prognosis and in whom antihypertensive drugs may be used over many years. The benefits of effectively treating orthostatic hypotension, thus reducing the likelihood of trauma and improving their quality of life, should be weighed against the long term risks.

**Neurally mediated syncope**

This depends upon the cause, the provoking factors, the disability caused, and whether the episodes are of the cardioinhibitory, vasodepressor or mixed type. Vasovagal syncope usually carries an excellent prognosis. Once the diagnosis is confirmed an important component of management is positive reassurance. Advice on non-pharmacological measures should be provided. These include salt repletion, an adequate fluid intake, avoidance of excessive use of stimulating substances such as caffeine, and, when needed, methods to enhance sympathetic activity and prevent pooling. Sympathetic activation techniques to raise blood pressure include those used during autonomic testing, such as the use of isometric hand exercise. Sitting with the head between the knees often is an effective means of preventing syncope.
There are a variety of measures to prevent venous pooling that include activation of the calf muscle pump during leg crossing and squatting while tying shoe laces. If necessary subjects should lie flat with the legs upright or with the head between the knees. Each subject should decide on which method to use effectively in different situations. This is of value especially in those who have a suitable window of warning before they lose consciousness. In vasodepressor syncope, if drugs are needed, low dose fludrocortisone and sympathomimetics can be used. Ephedrine is contraindicated if tachycardia is a problem; midodrine is the alternative. In those with a predominant cardio-inhibitory component a demand pacemaker needs consideration, especially when there is minimal warning before fainting. Cognitive behavioural psychotherapy is helpful if there is co-existing phobia, panic attack or anxiety disorder. The 5-hydroxytryptamine and noradrenaline uptake inhibitors also have a role.

In carotid sinus hypersensitivity, a cardiac demand pacemaker often is needed. When vasodepression persists following pacemaker insertion, vasopressor agents including midodrine should be considered. Caution should be exercised as these patients often are elderly and may have vascular disease or prostatic hypertrophy that increase the tendency to side effects. In unilateral hypersensitivity, carotid sinus denervation needs consideration.

In situational syncope, management should be directed towards the underlying cause and pathophysiological basis. In micturition syncope, that mainly occurs in the male, advice is needed to avoid factors (such as alcohol) which contribute; the bladder should be emptied while sitting rather than standing.

Hypertension
Hypertension caused by increased sympathetic nervous activity in the Guillain-Barré syndrome and subarachnoid haemorrhage may respond to propranolol and other sympatholytic agents. In high spinal cord injuries, determining and rectifying the provoking cause of autonomic dysreflexia is crucial, as the key is prevention. A range of drugs, based on knowledge of the pathophysiological mechanisms, can be used to prevent or reduce hypertension in such patients (Table 3).

| Table 3 Some of the drugs used in reducing hypertension in management of autonomic dysreflexia, classified according to their major site of action on the reflex arc and target organs |
|---------------------------------|---------------------------------|
| **Afferent**                    | **Topical lignocaine**          |
| **Spinal cord**                 | **Clonidine**                   |
|                                  | **Reserpine**                   |
|                                  | **Spinal anaesthetics**         |
| **Efferent**                    | **Sympathetic ganglia**         |
|                                  | **Hexamethonium**               |
|                                  | **Guanethidine**                |
|                                  | **Phenoxybenzamine**            |
| **Sympathetic nerve terminals** | **α Adrenoceptors**             |
|                                  | **Blood vessels**               |
| **Target organs**               | **Glyceryl trinitrate**         |
|                                  | **Nifedipine**                  |

*Clonidine and reserpine have multiple effects, some of which are peripheral.


SUDOMOTOR DISORDERS

Anhidrosis
The ensuing problems include dry skin, hyperthermia, and vasomotor collapse in hot weather. Dry skin is helped by suitable emollients. Prevention of hyperthermia is important by avoiding exposure to heat and ensuring a suitable microenvironment ideally by air conditioning. Mechanisms to aid heat loss include tepid sponging to aid evaporation, fans to enhance convection loss, and the ingestion of cool drinks. In severe hyperpyrexia, immersion in a cold bath may be needed.

Hyperhidrosis
Management depends upon the underlying cause, the sites involved, and the functional and emotional disability. In localised hyperhidrosis over the palms and soles, astringents containing glutaraldehyde and antiperspirants containing aluminium salts may reduce sweating. Iontophoresis has been used in palmar and plantar hyperhidrosis. Low dose pharmacotherapy includes anticholinergics and centrally acting sympatholytics. The former include propantheline bromide in a dose of 15 mg three times daily. Side effects include a dry mouth. Glaucomea should be excluded before use. Low dose clonidine (25–50 µg three times daily) may benefit those with a central or emotional component, and also may reduce facial flushing. Topical anticholinergic cream (hyoscine hydrobromide or glycopyrrolate) may be helpful in localised hyperhidrosis. Botulinum toxin is successful in hyperhidrosis affecting the axillae, palms, and face; injections may need to be repeated.

When these measures fail, surgical intervention using percutaneous endoscopic transthoracic sympathectomy, with ablation of prevertebral sympathetic ganglia from T2 to T4, should be considered. Ablation of T1/T2 also is used in facial flushing. In some, compensatory hyperhidrosis below the anhidrotic region can be extremely troublesome.

ALIMENTARY SYSTEM

Xerostomia is helped by artificial saliva. Excessive salivation responds to botulinum injection. Achalasia of the oesophagus may require dilatation, botulinum injection or surgery. In MSA with oropharyngeal dysphagia, advice should be provided on the type and consistency of food; severe dysfunction increases the risk of tracheal aspiration and a feeding gastrostomy tube may be needed. The dopamine antagonists, metoclopramide and domperidone, increase gastric emptying in gastroparesis, as does the macrolide erythromycin that stimulates motlin receptors. Peptic ulceration occurs in the early stages after high spinal cord injury and prophylaxis includes H2 antagonists (cimetidine and ranitidine) and proton pump inhibitors (omeprazole). In diarrhea caused by bacterial overgrowth, as in the blind loop syndrome, broad spectrum antibiotics (neomycin or tetracycline) may be the initial step before using codeine phosphate or other opiates based anti diarrhoeal agents. The somatostatin analogue, octreotide, may reduce diarrhoea in amyloidosis and diabetic autonomic neuropathy. Aperients and laxatives, together with a high fibre diet, are needed in constipation.

URINARY TRACT

In outflow tract obstruction, procedures that include prostatectomy, transurethral resection, or sphincterotony may be needed. Surgical procedures often induce or worsen incontinence in MSA. Bladder dysfunction may be helped by drugs that influence detrusor muscle activity (anticholinergics) or
Doses of decarboxylase inhibitors. The monoamine oxidase B
inhibitor, selegiline, has been used in combination with
L-dopa and also may worsen orthostatic hypertension. It also
may cause hypertension in Parkinson’s disease by mecha-
nisms that include the central effects of its metabolite,
methyl-amphetamine. Amantidine may provide motor benefit
without lowering blood pressure. Dopaminergic agonists may
be effective but it is unclear if they worsen orthostatic
hypotension. With time there often is refractoriness to
anti-parkinsonian drugs in MSA. There is no effective
pharmacotherapy for cerebellar deficits in MSA. Supportive
therapy using disability aids should be provided.

There is limited evidence that transplantation of the
pancreas in diabetes mellitus, and of the liver in familial amy-
l oid neuropathy, may halt the neuropathy in these otherwise
relentlessly progressive disorders.

CONCLUSION
The management of autonomic diseases needs to consider
local organ dysfunction, the underlying or associated disease,
and integrative components often needing specialist care
involving different specialities (table 4). Of particular impor-
tance, especially in the generalised disorders, is the need for a
holistic approach. Management should involve not only the
patient, but the family, carers, and the community.

REFERENCES AND FURTHER READING
2 Alam M, Smith GD, Bleasdale-Barr K, et al. Effects of the peptide release
inhibitor, octreotide, on daytime hyponatremia and on nocturnal
3 Appenzeller O, Orb E, eds. The autonomic nervous system. An
introduction to basic clinical concepts, 5th ed. Amsterdam: Elsevier
4 Churchyard A, Mathias CJ, Boonkongchuen P, et al. Autonomic effects of
selegiline: possible cardiovascular toxicity in Parkinson’s disease. J Neurol
Neurosurg Psychiatry 1997;63:228–34.
5 Colosimo C, Pezzella FR. The symptomatic treatment of multiple system
6 Cooper VL, Hainsworth R. Effects of dietary salt on orthostatic tolerance,
blood pressure and baroreceptor sensitivity in patients with syncope. Clin
7 Benditt DG. Cardiac pacing for prevention of vasovagal syncope. J Am
8 Harcourt J, Sprougs P, Mathias CJ, et al. Sleep-related breathing
disorders in the Shy-Drager syndrome. Observations on investigation and

*Recommended

Want to know more?

Data supplements

Limited space in printed journals means that interesting data and other material are often edited out of articles; however, limitless cyberspace means that we can include this information online. Look out for additional tables, references, illustrations.

www.jnnp.com
Autonomic diseases: management

Christopher J Mathias

J Neurol Neurosurg Psychiatry 2003 74: iii42-iii47
doi: 10.1136/jnnp.74.suppl_3.iii42

Updated information and services can be found at:
http://jnnp.bmj.com/content/74/suppl_3/iii42

These include:

References
This article cites 18 articles, 3 of which you can access for free at:
http://jnnp.bmj.com/content/74/suppl_3/iii42#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Hypertension (380)
- Parkinson's disease (690)
- Brain stem / cerebellum (670)
- Drugs: CNS (not psychiatric) (1945)
- Movement disorders (other than Parkinsons) (766)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/